US researchers have developed a more sensitive method of detecting
whether athletes have taken drugs to artificially boost
testosterone which increases physical performance.
Australian drug delivery specialist Acrux has reported positive
results in Phase II trials of its innovative under-arm lotion
formulation for testosterone replacement therapy.
Scientists have determined the precise molecular structure of a
potential new target for treating prostate cancer, a disease driven
in part by abnormal testosterone activity, which affects one in six
American men.
Debiopharm of Switzerland has won approval for a three-month depot
formulation of Pamorelin (triptorelin pamoate), a drug to treat
prostate cancer, based on its proprietary polymer-based drug
delivery technology.